Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis-Reference-Cited by-同舟云学术

Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis

Published:2025-02 Issue: Volume:Volume 18 Page:1639-1656
ISSN:1178-7031
Container-title:Journal of Inflammation Research
language:en
Short-container-title:JIR

Author:

Wu Xuanlin^ORCID,Pan Tao,Fang Zhihao,Hui Titi,Yu Xiaoxiao,Liu Changxu,Guo Zihao,Liu Chang

Publisher

Informa UK Limited

Reference49 articles.

1. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD

2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

3. European Association for the Study of the L. European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines on the management of metab olic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031

4. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

5. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Preclinical Biomarkers of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) versus MASLD and Increased Alcohol Intake and the Impact of Diet;The American Journal of Pathology;2025-06

2. Refining the Role of EGR1 as a Biomarker in MASLD [Letter];Journal of Inflammation Research;2025-02